Torrisi SE, Kahn N, Wälscher J, et al. - Researchers analyzed the effects of antifibrotic drugs in patients with fibrosing non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung diseases (ILDs) with a progressive phenotype during immunosuppressive therapy. In this retrospective analysis, they analyzed 11 patients who received treatment with antifibrotic drugs (8 males, mean age 62 ± 12.8 years, mean FVC(forced vital capacity)% 62.8 ± 22.3, mean diffusing capacity of the lung for carbon monoxide% 35.5 ± 10.7, median follow-up under antifibrotic treatment 11.1 months). Prior to the start of antifibrotic treatment, median FVC at time points − 24, − 12, − 6 was 56, 56, 50%, respectively, and was 44% at the time of initiation and 46.5% at 6 months following initiation. General good tolerability of antifibrotic treatment was revealed and dose reduction and early termination were required in 2 cases (rash and nausea) and in 3 cases, respectively. The possible worth of antifibrotic therapy in treating patients with progressive fibrosing non-IPF ILD was suggested in this study if no other treatment choices are available currently.